ArticleNature cancer2021
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers.
0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed
37.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
257 citing papers in PubMed, 361 citations in OpenAlex.
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Mitochondrial Metabolic Reprogramming in Glioma: Mechanisms of Tumorigenesis and Implications for Clinical Therapy.CNS neuroscience & therapeutics · 2026Review
- Next-generation therapeutics for glioblastoma: Challenges and future directions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.Neuro-oncology · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- A Coordinated Mitochondrial Genome Expression Program Marks a Differentiated Neural-Lineage and Synaptic Transcriptional State in Lower-Grade Glioma.International journal of molecular sciences · 2026Article
- LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming.Cell death & disease · 2026Article
- Spatial Omics Technologies in Glioblastoma Research: Principles, Applications, and Best Practices.Genes · 2026Review
- Systemic Drug Effects in Vortioxetine-Induced Time-Series Datasets.International journal of molecular sciences · 2026Article
- 1,25D3 reprograms mitochondrial quality control via sirtuin and sensitizes glioblastoma to chemotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- ERO1a fosters glioblastoma aggressiveness and metabolic flexibility by regulating mitochondria-associated membrane dynamics.Nature cell biology · 2026Article
- A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.iScience · 2026Article
- Patient-derived glioblastoma cultures preserve respiration phenotypes during ex vivo maintenance and show sex-associated differences in migration.Acta neuropathologica communications · 2026Article
- Observation of Acetylcholine Secretion on Living Glioblastoma Cells.ACS measurement science au · 2026Article
- T2Pdecoder enables protein-centric analyses from transcriptomic data.Nature communications · 2026Article
- Single-nucleus multiomics unveils malignant cellular states, regulatory architectures and microenvironmental reorganization across the G-CIMP epigenomic transition in IDH-mutant glioma.bioRxiv : the preprint server for biology · 2026Article
- Mitochondria transfer in glioblastoma.Neuro-oncology · 2026Review
- Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.Nature cancer · 2026Article
- Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities.Cell death discovery · 2026Review
- A longitudinal single-cell and spatial multiomic atlas of pediatric high-grade glioma.Cell reports. Medicine · 2026Article
197 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 7 institutions in 4 countries.
Luciano Garofano *Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8582-0865
Simona Migliozzi *Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Young Taek Oh *Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Fulvio D'AngeloInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4940-4693
Ryan D NajacInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Aram KoInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Brulinda FrangajInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Francesca Pia CarusoDepartment of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy.ORCID http://orcid.org/0000-0002-2206-1459
Kai YuBiomedical Pioneering Innovation Center, School of Life Sciences, Peking University, Beijing, China.
Jinzhou YuanDepartment of Systems Biology, Columbia University Medical Center, New York, NY, USA.
Wenting ZhaoDepartment of Systems Biology, Columbia University Medical Center, New York, NY, USA.
Anna Luisa Di StefanoInserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau et de la Moelle épinière, Paris, France.
Franck BielleInserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau et de la Moelle épinière, Paris, France.
Tao JiangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-7008-6351
Peter SimsDepartment of Systems Biology, Columbia University Medical Center, New York, NY, USA.
Mario L SuvàDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Fuchou TangBiomedical Pioneering Innovation Center, School of Life Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-8625-7717
Xiao-Dong SuBiomedical Pioneering Innovation Center, School of Life Sciences, Peking University, Beijing, China.
Michele CeccarelliDepartment of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy.ORCID http://orcid.org/0000-0002-4702-6617
Marc SansonInserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau et de la Moelle épinière, Paris, France.
Anna LasorellaInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA. al2179@columbia.edu.ORCID http://orcid.org/0000-0002-1839-5421
Antonio IavaroneInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA. ai2102@columbia.edu.ORCID http://orcid.org/0000-0002-0683-4634
Columbia University Irving Medical Center · USCentre National de la Recherche Scientifique · FRPeking University · CNBiogem · ITBroad Institute · USCapital Medical University · CNUniversity of Naples Federico II · IT
Funding
Topology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4MOncogenic mechanisms, molecular stratification and therapeutic targets of brain tumorsR35CA253183 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Antonio Iavarone · 2021 to 2026
$5.2MSingle Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment RecurrenceR01NS103473 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JEFFREY N BRUCE, Peter Canoll · 2017 to 2026
$4.3MThe role of Id proteins in tumor development and angiogenesis in the brainR01CA101644 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LASORELLA, ANNA · 2003 to 2013
$3.5MIdentification and modeling of driver genetic modules in glioblastomaR01CA179044 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2014 to 2018
$2.3MEvolution and targeting of the functional states of glioblastomaR01CA268592 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Antonio Iavarone, ANNA LASORELLA · 2022 to 2026
$2.0MThe role of the LZTR1 ubiquitin ligase in stem cells and cancerR01CA190891 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO · 2015 to 2019
$1.9MThe mechanisms driving brain oncogenesis by FGFR-TACC gene fusionsR01CA178546 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO · 2014 to 2018
$1.8MMechanisms of ID2 regulation in gliomaR01CA239721 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LASORELLA, ANNA · 2019 to 2023
$1.8MThe Ureb-1 ubiquitin ligase in neural stem cells and cancerR01CA131126 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LASORELLA, ANNA · 2008 to 2012
$1.6MThe Huwe1 ubiquitin ligase regulates mitosis, genomic stability and oncogenesis.R01CA239698 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO · 2019 to 2021
$1.1MNCI NIH HHS R01 CA101644NCI NIH HHS R01 CA131126NCI NIH HHS R01 CA178546NCI NIH HHS R01 CA179044NCI NIH HHS R01 CA190891NCI NIH HHS R01 CA239698NCI NIH HHS R01 CA239721NCI NIH HHS R01 CA268592NCI NIH HHS R35 CA253183NCI NIH HHS U54 CA193313
Abstract
The transcriptomic classification of glioblastoma (GBM) has failed to predict survival and therapeutic vulnerabilities. A computational approach for unbiased identification of core biological traits of single cells and bulk tumors uncovered four tumor cell states and GBM subtypes distributed along neurodevelopmental and metabolic axes, classified as proliferative/progenitor, neuronal, mitochondrial and glycolytic/plurimetabolic. Each subtype was enriched with biologically coherent multiomic features. Mitochondrial GBM was associated with the most favorable clinical outcome. It relied exclusively on oxidative phosphorylation for energy production, whereas the glycolytic/plurimetabolic subtype was sustained by aerobic glycolysis and amino acid and lipid metabolism. Deletion of the glucose-proton symporter
Indexed as
GlioblastomaGliomaGlycolysisHumansMitochondriaOxidative Phosphorylation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.